Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages

  Di Mario, Simona ^a   Basevi, Vittorio ^a   Borsari, Silvana ^b   Balduzzi, Sara ^c   Magrini, Nicola ^a  

^a Guideline Development in Reproductive Health   (Italy)

^b Programme on Women's Health   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; ALUMINUM HYDROXIDE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LIPID A;

ADOLESCENT; ADULT; DRUG EFFICACY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTRAUTERINE CONTRACEPTIVE DEVICE; LETTER; NORMAL HUMAN; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SOCIAL STATUS; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; ADENOCARCINOMA; IMMUNOLOGY; NOTE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84856450984     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70054-2     Document Type: Letter

References (3)

1. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99. for the HPV PATRICIA Study Group.
2. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170. for the HPV PATRICIA study group.
3. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. for the HPV PATRICIA study group.